

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1. (Original) A method of prophylaxis of a disease associated with amyloid deposits of A $\beta$  in the brain of a patient, comprising administering an effective regime of a fragment of A $\beta$ , wherein the fragment induces antibodies that specifically bind to A $\beta$  at one or more epitopes between residues 12 and 43 without inducing antibodies that specifically bind to one or more epitopes between residues 1-11, and the fragment is not A $\beta$ 13-28, 17-28, 25-35, 35-40, 33-42 or 35-42, whereby the induced antibodies specifically bind to soluble A $\beta$  in the patient thereby inhibiting formation of amyloid deposits of A $\beta$  in the brain from the soluble A $\beta$ , and thereby effecting prophylaxis of the disease

2-5. (Canceled)

6. (Original) The method of claim 1, wherein the fragment is selected from the group consisting of A $\beta$ 15-21, A $\beta$ 16-22, A $\beta$ 17-23, A $\beta$ 18-24, A $\beta$ 19-25, A $\beta$ 15-22, A $\beta$ 16-23, A $\beta$ 17-24, A $\beta$ 18-25, A $\beta$ 15-23, A $\beta$ 16-24, A $\beta$ 17-25, A $\beta$ 18-26, A $\beta$ 15-24, A $\beta$ 16-25, and A $\beta$ 15-25.

7. (Canceled)

8. (Original) A method of prophylaxis of a disease associated with amyloid deposits of A $\beta$  in the brain of a patient, comprising administering an effective regime of a fragment of A $\beta$ , wherein the fragment is selected from the group consisting of A $\beta$ 15-21, A $\beta$ 16-22, A $\beta$ 17-23, A $\beta$ 18-24, A $\beta$ 19-25, A $\beta$ 15-22, A $\beta$ 16-23, A $\beta$ 17-24, A $\beta$ 18-25, A $\beta$ 15-23, A $\beta$ 16-24, A $\beta$ 17-25, A $\beta$ 18-26, A $\beta$ 15-24, A $\beta$ 16-25, and A $\beta$ 15-25, and thereby effect prophylaxis of the disease.

9-25. (Canceled)

26. (Currently Amended) The method of ~~any of the preceding claims~~ claims 1 or 8, wherein the fragment is administered with an adjuvant that increases the level of antibodies induced by the fragment.

27. (Canceled)

28. (Currently Amended) The method of ~~any of the preceding claims~~ claims 1 or 8, wherein the fragment is administered by administering a polynucleotide encoding the fragment, wherein the polynucleotide is expressed to produce the fragment in the patient.

29-31. (Canceled)

32. (Original) The method of claim 1, wherein the fragment is linked to a carrier molecule to form a conjugate.

33-47. (Canceled)

48. (Original) A method of treating a disease associated with amyloid deposits of A $\beta$  in the brain of a patient, comprising administering an effective regime of a fragment of A $\beta$ , wherein the fragment induces antibodies that specifically bind to A $\beta$  at one or more epitopes between residues 12 and 43 without inducing antibodies that specifically bind to one or more epitopes between residues 1-11, and the fragment, 33-42 A $\beta$ 13-28, 17-28, 25-35, 35-40 or 35-42, whereby the induced antibodies specifically bind to soluble A $\beta$  in the patient thereby inhibiting formation of amyloid deposits of A $\beta$  in the brain from the soluble A $\beta$ , and thereby treat the disease.

49-52. (Canceled)

53. (Original) The method of claim 48, wherein the fragment is selected from the group consisting of A $\beta$ 15-21, A $\beta$ 16-22, A $\beta$ 17-23, A $\beta$ 18-24, A $\beta$ 19-25, A $\beta$ 15-22, A $\beta$ 16-23, A $\beta$ 17-24, A $\beta$ 18-25, A $\beta$ 15-23, A $\beta$ 16-24, A $\beta$ 17-25, A $\beta$ 18-26, A $\beta$ 15-24, A $\beta$ 16-25, and A $\beta$ 15-25.

54. (Canceled)

55. (Original) A method of treating a disease associated with amyloid deposits of A $\beta$  in the brain of a patient, comprising administering an effective regime of a fragment of A $\beta$ , wherein the fragment is selected from the group consisting of A $\beta$ 15-21, A $\beta$ 16-22, A $\beta$ 17-23, A $\beta$ 18-24, A $\beta$ 19-25, A $\beta$ 15-22, A $\beta$ 16-23, A $\beta$ 17-24, A $\beta$ 18-25, A $\beta$ 15-23, A $\beta$ 16-24, A $\beta$ 17-25, A $\beta$ 18-26, A $\beta$ 15-24, A $\beta$ 16-25, and A $\beta$ 15-25, and thereby treat the disease.

56-72. (Canceled)

73. (Currently Amended) The method of ~~any of the preceding claims~~ claims 48 or 55, wherein the fragment is administered with an adjuvant that increases the level of antibodies induced by the fragment.

74. (Canceled)

75. (Currently Amended) The method of ~~any of the preceding claims~~ claims 48 or 55, wherein the fragment is administered by administering a polynucleotide encoding the fragment, wherein the polynucleotide is expressed to produce the fragment in the patient.

76-78. (Canceled)

79. (Original) The method of claim 55, wherein the fragment is linked to a carrier to form a conjugate.

80-94. (Canceled)

95. (Original) A pharmaceutical composition comprising a fragment of A $\beta$  as defined in any of claims 48-55 and an adjuvant.

96-102. (Canceled)